FINNENCE ▪ THE WIRE FILE
THE WIRE · № 56612
News■ Unclear/unknown
AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress
KINDNews
DIRECTION■ Unclear/unknown
SOURCES4
ENTITIES1
STORY SIZE4 RECORDS
FIRST SEEN2026-09-30 05:00 UTC
LAST UPDATE2026-09-30 05:57 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Clinical data presentations can support future label expansion and prescribing, but abstracts alone rarely move revenue near term.
Pipeline visibility matters, but no new approval or sales guidance
CATALYST TO WATCH
Peer-reviewed results or regulatory submissions from these data
MAIN RISK
Abstracts may lack pivotal endpoints or statistical significance
FULL DISPATCH
AbbVie presents 60 abstracts and presentations from a robust portfolio spanning across alopecia areata, atopic dermatitis, hidradenitis suppurativa, non-segmental vitiligo, psoriasis and psoriatic arthritis New data for risankizumab and upadacitinib provide further evidence supporting...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
UPDATED 4 TIMES · FIRST 2026-09-30 05:00 UTC · LAST 2026-09-30 05:57 UTC2026-09-30 05:00 UTCNewsAbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV CongressCURRENT RECORD
2026-09-30 05:00 UTCNewsFactory activity returns to expansion in a positive sign for China's economy - Newsday
2026-09-30 05:30 UTCNewsAbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026
2026-09-30 05:57 UTCNewsBreaking the Safety Barrier: Insilico Medicine Nominates ISM1354, the Next-Generation Small Molecule GIPR Antagonist
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 20262026-09-30 05:30 UTC
AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 20262026-09-30 05:30 UTC
→CORRELATIONshares Healthcare
Breaking the Safety Barrier: Insilico Medicine Nominates ISM1354, the Next-Generation Small Molecule GIPR Antagonist2026-09-30 05:57 UTC
Breaking the Safety Barrier: Insilico Medicine Nominates ISM1354, the Next-Generation Small Molecule GIPR Antagonist2026-09-30 05:57 UTC
→CORRELATIONshares Healthcare
Wake County leaders tout growth, defend WakeMed-Atrium merger2026-09-29 23:13 UTC
Wake County leaders tout growth, defend WakeMed-Atrium merger2026-09-29 23:13 UTC
←CORRELATIONshares Healthcare
Merger would create one of Minnesota’s largest health systems2026-09-29 14:52 UTC
Merger would create one of Minnesota’s largest health systems2026-09-29 14:52 UTC
←CORRELATIONshares Healthcare
Merger would create one of Minnesota’s largest health systems2026-09-29 14:52 UTC
Merger would create one of Minnesota’s largest health systems2026-09-29 14:52 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.